PL3378859T3 - Pochodna benzofuranu, sposób jej wytwarzania i jej zastosowanie w medycynie - Google Patents
Pochodna benzofuranu, sposób jej wytwarzania i jej zastosowanie w medycynieInfo
- Publication number
- PL3378859T3 PL3378859T3 PL16865671T PL16865671T PL3378859T3 PL 3378859 T3 PL3378859 T3 PL 3378859T3 PL 16865671 T PL16865671 T PL 16865671T PL 16865671 T PL16865671 T PL 16865671T PL 3378859 T3 PL3378859 T3 PL 3378859T3
- Authority
- PL
- Poland
- Prior art keywords
- medicine
- preparation
- benzofuran derivative
- benzofuran
- derivative
- Prior art date
Links
- 150000001907 coumarones Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510800975 | 2015-11-19 | ||
| PCT/CN2016/104318 WO2017084494A1 (zh) | 2015-11-19 | 2016-11-02 | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 |
| EP16865671.8A EP3378859B1 (en) | 2015-11-19 | 2016-11-02 | Benzofuran derivative, preparation method thereof and use thereof in medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3378859T3 true PL3378859T3 (pl) | 2020-04-30 |
Family
ID=58717310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16865671T PL3378859T3 (pl) | 2015-11-19 | 2016-11-02 | Pochodna benzofuranu, sposób jej wytwarzania i jej zastosowanie w medycynie |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10759787B2 (pl) |
| EP (1) | EP3378859B1 (pl) |
| JP (1) | JP6828229B2 (pl) |
| KR (2) | KR20180081587A (pl) |
| CN (1) | CN107428742B (pl) |
| AU (1) | AU2016357900B2 (pl) |
| BR (1) | BR112018007876B1 (pl) |
| DK (1) | DK3378859T3 (pl) |
| ES (1) | ES2760510T3 (pl) |
| HR (1) | HRP20192209T1 (pl) |
| HU (1) | HUE047785T2 (pl) |
| LT (1) | LT3378859T (pl) |
| MX (1) | MX380122B (pl) |
| PL (1) | PL3378859T3 (pl) |
| PT (1) | PT3378859T (pl) |
| RS (1) | RS59763B1 (pl) |
| RU (1) | RU2727198C2 (pl) |
| SI (1) | SI3378859T1 (pl) |
| TW (1) | TWI718207B (pl) |
| WO (1) | WO2017084494A1 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| TWI810185B (zh) * | 2017-05-18 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種ｅｚｈ２抑制劑與ｂｔｋ抑制劑聯合在製備治療腫瘤的藥物中的用途 |
| MX386586B (es) * | 2017-05-18 | 2025-03-19 | Jiangsu Hengrui Medicine Co | Cristal de base libre de derivados benzofurano y método de preparación. |
| WO2019091450A1 (zh) | 2017-11-10 | 2019-05-16 | 江苏恒瑞医药股份有限公司 | 一种苯并呋喃衍生物的制备方法 |
| NZ766447A (en) | 2018-01-31 | 2021-12-24 | Mirati Therapeutics Inc | Prc2 inhibitors |
| CN110179796B (zh) * | 2018-02-23 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种苯并呋喃类衍生物的组合物及制备方法 |
| CN110563722A (zh) * | 2018-06-06 | 2019-12-13 | 上海青煜医药科技有限公司 | 吡啶或哒嗪并环化合物及其应用 |
| WO2020063863A1 (zh) * | 2018-09-29 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途 |
| CN113631541B (zh) | 2019-03-25 | 2024-10-01 | 上海华汇拓医药科技有限公司 | 酰胺类化合物制备方法及其在医药领域的应用 |
| WO2020219448A1 (en) | 2019-04-22 | 2020-10-29 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as prc2 inhibitors |
| WO2020220562A1 (zh) * | 2019-04-29 | 2020-11-05 | 上海和誉生物医药科技有限公司 | 苯并呋喃-6-甲酰胺衍生物、其制备方法和药学上的应用 |
| WO2020228591A1 (zh) * | 2019-05-10 | 2020-11-19 | 江苏恒瑞医药股份有限公司 | 一种6-取代氨基苯并呋喃化合物的制备方法 |
| CN110003187B (zh) * | 2019-05-10 | 2021-11-05 | 南京工业大学 | 一种多氟烷基取代苯并呋喃类化合物及其制备方法 |
| CN110172448B (zh) * | 2019-05-30 | 2020-07-28 | 中南大学湘雅二医院 | 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系 |
| CN112007162B (zh) * | 2019-05-30 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途 |
| JP7541538B2 (ja) | 2019-06-05 | 2024-08-28 | ミラティ セラピューティクス，インク． | 癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体 |
| CN114040776B (zh) * | 2019-06-28 | 2024-05-14 | 江苏恒瑞医药股份有限公司 | Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途 |
| TW202126302A (zh) * | 2019-09-30 | 2021-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｅｚｈ２抑制劑與免疫檢查點抑制劑、酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途 |
| TW202114663A (zh) * | 2019-09-30 | 2021-04-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | EZH2抑制劑與含有TGF-β受體的融合蛋白聯合在製備治療腫瘤的藥物中的用途 |
| TW202114670A (zh) * | 2019-09-30 | 2021-04-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 一種ezh2抑制劑與cdk4/6抑制劑聯合在製備治療腫瘤藥物中的用途 |
| CN112870365A (zh) * | 2019-11-29 | 2021-06-01 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |
| JP2024530310A (ja) * | 2021-08-30 | 2024-08-16 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Ｔ細胞リンパ腫治療薬の調製におけるｅｚｈ２阻害剤の使用 |
| IL312137A (en) | 2021-10-15 | 2024-06-01 | Jiangsu Hengrui Pharmaceuticals Co Ltd | A method of preparation of a benzofuran derivative |
| EP4536658A1 (en) | 2022-06-13 | 2025-04-16 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
| US20250270191A1 (en) | 2022-06-13 | 2025-08-28 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| US20250282742A1 (en) * | 2024-03-08 | 2025-09-11 | Automera PTE. LTD | Benzofuran derivatives for targeting autophagy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110275630A1 (en) | 2003-06-02 | 2011-11-10 | Abbott Laboratories | Isoindolinone kinase inhibitors |
| ES2377280T3 (es) * | 2008-02-14 | 2012-03-26 | F. Hoffmann-La Roche Ag | Compuestos heterocíclicos antivíricos |
| ES2528269T3 (es) * | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| JP5864546B2 (ja) | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インダゾール |
| EA023788B1 (ru) * | 2010-05-07 | 2016-07-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Производные индола и фармацевтические композиции на их основе |
| EP2410171A1 (en) | 2010-07-23 | 2012-01-25 | Ewt Ip B.V. | Wind turbine having a rotor with hub |
| SG180031A1 (en) | 2010-10-15 | 2012-05-30 | Agency Science Tech & Res | Combination treatment of cancer |
| EP3323820B1 (en) * | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| WO2013039988A1 (en) | 2011-09-13 | 2013-03-21 | Glax0Smithkline Llc | Azaindazoles |
| CA2850570A1 (en) * | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
| WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| US9505745B2 (en) | 2013-04-30 | 2016-11-29 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
| US9822103B2 (en) * | 2013-11-22 | 2017-11-21 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| HUE049417T2 (hu) * | 2014-03-17 | 2020-09-28 | Daiichi Sankyo Co Ltd | 1,3-benzodioxol származékok mint EZHl és/vagy EZH2 inhibitorok |
-
2016
- 2016-11-02 DK DK16865671.8T patent/DK3378859T3/da active
- 2016-11-02 RU RU2018119173A patent/RU2727198C2/ru active
- 2016-11-02 PL PL16865671T patent/PL3378859T3/pl unknown
- 2016-11-02 LT LTEP16865671.8T patent/LT3378859T/lt unknown
- 2016-11-02 AU AU2016357900A patent/AU2016357900B2/en active Active
- 2016-11-02 SI SI201630514T patent/SI3378859T1/sl unknown
- 2016-11-02 HR HRP20192209TT patent/HRP20192209T1/hr unknown
- 2016-11-02 HU HUE16865671A patent/HUE047785T2/hu unknown
- 2016-11-02 US US15/775,958 patent/US10759787B2/en active Active
- 2016-11-02 KR KR1020187016692A patent/KR20180081587A/ko not_active Ceased
- 2016-11-02 CN CN201680013259.7A patent/CN107428742B/zh active Active
- 2016-11-02 RS RS20191628A patent/RS59763B1/sr unknown
- 2016-11-02 KR KR1020257005120A patent/KR20250028514A/ko active Pending
- 2016-11-02 WO PCT/CN2016/104318 patent/WO2017084494A1/zh not_active Ceased
- 2016-11-02 ES ES16865671T patent/ES2760510T3/es active Active
- 2016-11-02 EP EP16865671.8A patent/EP3378859B1/en active Active
- 2016-11-02 MX MX2018005019A patent/MX380122B/es unknown
- 2016-11-02 BR BR112018007876-0A patent/BR112018007876B1/pt active IP Right Grant
- 2016-11-02 JP JP2018523005A patent/JP6828229B2/ja active Active
- 2016-11-02 PT PT168656718T patent/PT3378859T/pt unknown
- 2016-11-16 TW TW105137422A patent/TWI718207B/zh active
-
2020
- 2020-07-22 US US16/935,407 patent/US11059811B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3378859T (lt) | Benzofurano darinys, jo gavimo būdas ir jo panaudojimas medicinoje | |
| PT3546457T (pt) | Derivado de pirazolo-heteroarílico, método de preparação e a utilização médica do mesmo | |
| HUE057289T2 (hu) | Oxopikolinamid-származék, annak elõállítási módszere és gyógyszerészeti felhasználása | |
| PT3214081T (pt) | Derivado de isoindolina, seu intermediário, seu método de preparação, sua composição farmacêutica e sua utilização | |
| PL3181560T3 (pl) | Pochodna pirydynoamidopirymidyny, sposób jej otrzymywania i zastosowanie | |
| SG11201608711RA (en) | Material itq-55, method for preparation and use | |
| IL256744A (en) | A new derivative of pyrizin, its preparation method and medical application | |
| IL290114A (en) | Pharmaceutical preparations, their preparation and uses | |
| IL257340A (en) | Converted benzaimidazoles, methods for their preparation and use as pharmaceuticals | |
| ZA201908091B (en) | Indole-formamide derivative, preparation method therefor and use thereof in medicine | |
| HUE058909T2 (hu) | Etomidátszármazék és köztitermék, eljárás elõállítására és alkalmazása | |
| IL252397A0 (en) | Pharmaceutical preparations, their preparation and uses | |
| PL3229843T3 (pl) | Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji | |
| SG11201609948YA (en) | Lobaplatin crystal, preparation method and pharmaceutical application | |
| IL252461A0 (en) | Alpha-asrylaldehyde ester, a method for its preparation and application | |
| EP3381921A4 (en) | GINKGOLIDE B DERIVATIVE AND METHOD OF PREPARING THEREOF AND USE THEREOF | |
| SG11201607530XA (en) | Hexose derivatives, preparation and uses thereof | |
| IL237283A0 (en) | Dldh and its derivatives, and preparations containing them for medical use | |
| IL251930B (en) | Benzylhydroxy derivatives, their preparation and medical uses |